Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or
amplified patients who progressed on or did not respond to available standard therapies.
Patients must have documented HER2 expression or amplification. The patient must have
exhausted available standard therapies. Patients will receive study drug as a single IV
infusion. Cycles will continue until disease progression or unacceptable toxicity.